ITI-1284-101 Study
Alzheimer’s Disease with Agitation
-
Open enrollment Study for Alzheimer's Disease with agitation
The main goal of this study is to evaluate the safety and effectiveness of a potential new drug in reducing agitation symptoms in people with Alzheimer’s disease. The investigational medicine targets brain chemicals—serotonin and dopamine—that help regulate thoughts, emotions, and behavior. The study will explore whether adjusting these chemical levels can help decrease agitation.
-
Participation involves:
- Screening period (lasting up to 4 weeks) - 1 study visit.
- Study treatment period (lasting about 12 weeks) - 13 study visits.
- Follow-up period (lasting about 30 days) - 1 study visit.
-
We are looking for patients who are:
- Are 55 years of age or older.
- Have been diagnosed with AD and are experiencing symptoms of agitation.
- Have at least 1 caregiver who will be able to support them during the study.
Application for Current Clinical Research Study
Research Study
ITI-1284-101 Study: Alzheimer's Disease (AD) with agitation
Please enter your Full Legal Name
-
What else do I need to consider?
Participation in the study is voluntary and can be stopped at any time. While there is no payment for joining, travel costs may be reimbursed. Study drugs and related tests are provided at no cost, and medical professionals will closely monitor the participant’s health. If the participant loses their caregiver, they will need to withdraw from the study.
